Nutrition Science Partners JV Approved

RNS Number : 2116C

Hutchison China Meditech Limited

12 April 2013

 



Hutchison China MediTech Limited ("Chi-Med")
(AIM: HCM)

Nestlé Health Science and Chi-Med complete regulatory approvals for the establishment of Nutrition Science Partners Joint Venture

London: Friday, 12 April 2013: Nestlé Health Science SA, a fully-owned subsidiary of Nestlé SA, and Chi-Med, today announce that all regulatory approvals required for the establishment of the 50/50 joint venture Nutrition Science Partners Limited ("NSP") have been received.

The purpose of NSP is to research, develop, manufacture and market worldwide novel medicines and nutritional products derived from botanical plant origins.  NSP will focus on gastrointestinal indications and may in the future expand into the metabolic disease and brain health areas. 

Ends

Enquiries

Chi-Med Christian Hogg, CEO	Telephone:      [phone]
Panmure Gordon (UK) Limited Richard Gray Andrew Potts Grishma Patel	Telephone:      [phone]
Citigate Dewe Rogerson Anthony Carlisle David Dible	Telephone:      [phone] Mobile:             [phone] Mobile:             [phone]

Notes to Editors

About Nestlé Health Science

Nestlé Health Science, a wholly-owned subsidiary of Nestlé, was formed in January 2011 to spearhead the development of science-based personalised nutritional solutions. Building on its core HealthCare Nutrition business, the company has ambitions to address chronic conditions in the area of Gastrointestinal Health, Metabolic Health and Brain Health. Nestlé Health Science offers nutritional solutions for people with specific dietary needs related to illnesses, disease states or the special challenges of different life stages. Nestlé Health Science employs around 3,000 people worldwide and has its headquarters in Lutry, Switzerland. For more information, please visit www.nestlehealthscience.com.

About Chi-Med

Chi-Med is the holding company of a healthcare group based primarily in China and was listed on the Alternative Investment Market of the London Stock Exchange in May 2006. It is focused on researching, developing, manufacturing and selling pharmaceuticals and health oriented consumer products.

Chi-Med is majority owned by Hutchison Whampoa Limited, an international company listed on the Main Board of The Stock Exchange of Hong Kong Limited.

About Hutchison MediPharma Limited ("HMP")

HMP is a novel drug R&D company focusing on discovering, developing and commercialising innovative therapeutics in oncology and autoimmune diseases.  With a team of around 200 scientists and staff, its pipeline is comprised of novel oral compounds for cancer and inflammation in development in North America, Europe, Australia and Greater China.

HMP is majority owned by Chi-Med.

 

END

 

 

MSCGGUGGCUPWUQP